MYO · MYOMO, INC.

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.

Cap structure and valuation

Cap structure
SP	$0.85
SO	38.6M
Options	0.0M
Warrants	5.1M
FD SO	43.8M
MC	$37.0M

Cash	$11.4M
Total debt	$10.9M
EV	$36.5M

TTM Multiples
EV / Revenue	0.9x
EV / EBITDA	—
MC / Net Income	—
EV / FCF	—
MC / FCF	—

MC = SP × FD SO. EV = MC + Debt − Cash. SP = previous yfinance close. Balance-sheet figures as of 2026-05-01. Multiples use TTM (sum of last 4 quarters); shown as "—" when the denominator is zero or negative.

Financial statements

	3/31/26	12/31/25	9/30/25	6/30/25
Total Revenue	10.11	11.35	10.09	9.65
Revenue YoY %	2.9%	(5.9%)	9.6%	28.3%
Cost of Revenue	3.21	3.57	3.65	3.60
Gross Profit	6.90	7.78	6.44	6.05
Gross Profit YoY %	4.4%	(9.6%)	(7.2%)	13.6%
Gross Margin %	68.2%	68.6%	63.8%	62.7%

SG&A	8.44	8.93	8.43	8.64
R&D	1.62	1.62	1.53	2.00
Operating Expense	10.06	10.56	9.96	10.64

Operating Income	(3.16)	(2.77)	(3.52)	(4.59)
Operating Income YoY %	10.3%	(1030.7%)	(267.3%)	(311.7%)
Operating Margin %	(31.2%)	(24.4%)	(34.9%)	(47.6%)
EBITDA	(2.87)	(2.51)	(3.27)	(4.40)
EBITDA Margin %	(28.3%)	(22.1%)	(32.4%)	(45.6%)

Pretax Income	(2.82)	(3.73)	(3.53)	(4.48)
Tax Provision	0.19	0.08	0.14	0.15
Net Income	(3.01)	(3.81)	(3.66)	(4.63)
Net Margin %	(29.8%)	(33.6%)	(36.3%)	(48.0%)

Diluted EPS	-$0.07	-$0.09	-$0.09	-$0.11
Basic EPS	-$0.07	-$0.09	-$0.09	-$0.11
Diluted Avg Shares	42.3	0.1	42.2	41.6
Basic Avg Shares	42.3	0.1	42.2	41.6

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Total Revenue	41.21	40.93	32.55	19.24	15.56
Revenue YoY %	0.7%	25.7%	69.2%	23.7%	—
Cost of Revenue	14.03	14.04	9.37	6.06	5.30
Gross Profit	27.18	26.89	23.19	13.18	10.25
Gross Profit YoY %	1.1%	16.0%	75.9%	28.6%	—
Gross Margin %	66.0%	65.7%	71.2%	68.5%	65.9%

SG&A	34.44	34.35	24.62	18.78	18.44
R&D	6.78	6.94	4.77	2.64	2.48
Operating Expense	41.22	41.29	29.39	21.41	20.93

Operating Income	(14.04)	(14.40)	(6.21)	(8.23)	(10.67)
Operating Income YoY %	2.5%	(132.0%)	24.6%	22.9%	—
Operating Margin %	(34.1%)	(35.2%)	(19.1%)	(42.8%)	(68.6%)
EBITDA	(13.05)	(13.54)	(6.00)	(8.07)	(10.48)
EBITDA Margin %	(31.7%)	(33.1%)	(18.4%)	(41.9%)	(67.4%)

Pretax Income	(14.56)	(15.07)	(5.82)	(7.99)	(10.65)
Tax Provision	0.55	0.50	0.37	0.16	0.07
Net Income	(15.12)	(15.57)	(6.18)	(8.15)	(10.72)
Net Income to Common	(15.12)	(15.60)	(6.20)	(8.10)	(10.72)
Net Margin %	(36.7%)	(38.1%)	(19.0%)	(42.3%)	(68.9%)

Diluted EPS	-$0.36	-$0.37	-$0.16	-$0.28	-$1.52
Basic EPS	-$0.36	-$0.37	-$0.16	-$0.28	-$1.52
Diluted Avg Shares	42.3	41.9	37.8	29.5	7.1
Basic Avg Shares	42.3	41.9	37.8	29.5	7.1

	3/31/26	12/31/25	9/30/25	6/30/25
Cash & Equivalents	11.40	14.13	12.55	14.24
Receivables	4.82	4.10	5.29	7.05
Inventory	3.55	3.12	3.65	4.13
Total Current Assets	25.66	27.56	22.95	28.04

Net PPE	2.24	2.21	3.71	2.91
Total Assets	36.75	38.64	34.08	38.67

Total Current Liabilities	9.39	8.35	9.20	11.75
Long-term Debt	10.93	11.22	2.42	1.33
Total Liabilities	27.75	27.23	19.45	21.06

Retained Earnings	(121.70)	(118.69)	(114.87)	(111.21)
Total Equity	9.00	11.40	14.63	17.62

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Cash & Equivalents	11.40	14.13	24.37	6.87	5.35
Receivables	4.82	4.10	3.83	2.38	1.90
Inventory	3.55	3.12	3.17	1.80	1.40
Total Current Assets	25.66	27.56	32.79	13.65	9.22

Net PPE	2.24	2.21	1.33	0.18	0.19
Total Assets	36.75	38.64	42.24	14.58	10.16

Total Current Liabilities	9.39	8.35	10.17	5.48	3.60
Long-term Debt	10.93	11.22	11.22	—	—
Total Liabilities	27.75	27.23	17.53	5.59	3.80

Retained Earnings	(121.70)	(118.69)	(103.11)	(96.93)	(88.78)
Total Equity	9.00	11.40	24.71	8.99	6.36

	3/31/26	12/31/25	9/30/25	6/30/25
Net Income	(3.01)	(3.81)	(3.66)	(4.63)
D&A	0.29	0.26	0.25	0.19
Stock-Based Comp	0.60	0.56	0.58	0.39
Operating Cash Flow	(2.20)	(1.14)	(1.83)	(8.87)

CapEx	(0.33)	1.24	(1.05)	(1.26)
Investing Cash Flow	(0.49)	(4.59)	0.19	(0.76)

Debt Issuance	—	0.00	(1.00)	—
Financing Cash Flow	0.00	7.51	(0.05)	4.00

Free Cash Flow	(2.53)	0.10	(2.88)	(10.12)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Net Income	(15.12)	(15.60)	(6.20)	(8.10)	(10.72)
D&A	0.99	0.86	0.21	0.16	0.19
Stock-Based Comp	2.14	2.08	0.87	1.12	1.19
Operating Cash Flow	(14.03)	(14.51)	(3.29)	(6.17)	(10.23)

CapEx	(1.40)	(1.74)	(1.36)	(0.15)	(0.11)
Investing Cash Flow	(5.66)	(7.06)	0.26	(2.03)	(0.31)

Debt Issuance	—	3.00	0.00	—	—
Debt Repayment	—	(4.00)	0.00	—	—
Financing Cash Flow	11.46	11.43	20.93	9.71	0.38

Free Cash Flow	(15.43)	(16.25)	(4.65)	(6.32)	(10.35)

	3/31/26	12/31/25	9/30/25	6/30/25
Current Ratio	2.73	3.30	2.49	2.39
Quick Ratio	2.36	2.93	2.10	2.03
Debt / Equity	3.08	2.39	1.33	1.20
EBITDA Margin %	(28.3%)	(22.1%)	(32.4%)	(45.6%)
Working Capital	16.27	19.21	13.75	16.29
Net Debt	(0.47)	(2.91)	(10.14)	(12.91)
ROE %	(33.4%)	(33.4%)	(25.0%)	(26.3%)
ROA %	(8.2%)	(9.9%)	(10.7%)	(12.0%)

	LTM	12/31/25	12/31/24	12/31/23	12/31/22
Current Ratio	2.73	3.30	3.22	2.49	2.56
Quick Ratio	2.36	2.93	2.91	2.16	2.17
Debt / Equity	3.08	2.39	0.71	0.62	0.60
EBITDA Margin %	(31.7%)	(33.1%)	(18.4%)	(41.9%)	(67.4%)
Working Capital	16.27	19.21	22.62	8.17	5.61
Net Debt	(0.47)	(2.91)	(13.15)	—	—
ROE %	(167.9%)	(136.6%)	(25.0%)	(90.6%)	(168.6%)
ROA %	(41.1%)	(40.3%)	(14.6%)	(55.9%)	(105.5%)

Insider activity (last 2 years)

Date Filed	Reporter	Relationship	Trans. Date	Code	Shares	Price	Total Value
2026-05-18	KIRK THOMAS F	Director	2026-05-18	P	43,401	$0.91	$39,495
2026-05-18	KIRK THOMAS F	Director	2026-05-15	P	31,605	$0.91	$28,748
2026-05-18	Manko Joseph M. Jr.	Director	2026-05-15	P	30,367	$0.89	$26,960
2026-05-18	Manko Joseph M. Jr.	Director	2026-05-14	P	170,830	$0.86	$146,948
2026-05-15	Mitchell Micah	Officer (Chief Commercial Officer)	2025-05-14	S	(90,231)	$0.86	-$77,689
2026-04-16	FEBBO WILLIAM J	Director	2026-04-14	A	45,000	—	$0
2026-04-14	HENRY DAVID A	Officer (Chief Financial Officer)	2026-04-13	F	(3,953)	$0.71	-$2,807
2026-04-14	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2026-04-10	A	16,666	—	$0
2026-04-14	HENRY DAVID A	Officer (Chief Financial Officer)	2026-04-10	A	12,500	—	$0
2026-04-14	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2026-04-10	A	19,395	—	$0
2026-03-17	Getz Heather C	Director	2026-03-16	P	20,000	$0.70	$13,972
2026-03-16	KIRK THOMAS F	Director	2026-03-13	P	72,000	$0.71	$51,113
2026-03-12	Getz Heather C	Director	2026-03-12	P	70,000	$0.73	$50,960
2026-01-14	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2026-01-12	A	11,637	—	$0
2026-01-14	HENRY DAVID A	Officer (Chief Financial Officer)	2026-01-12	A	8,727	—	$0
2025-11-24	KIRK THOMAS F	Director	2025-11-21	P	2,535	$0.72	$1,825
2025-11-24	KIRK THOMAS F	Director	2025-11-20	P	4,902	$0.72	$3,529
2025-11-21	Crowley Thomas Aloysius Jr.	Director	2025-11-19	P	385	$0.77	$295
2025-11-21	Crowley Thomas Aloysius Jr.	Director	2025-11-18	P	4,000	$0.73	$2,938
2025-09-11	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2025-09-09	G	(10,000)	—	$-0
2025-08-26	KIRK THOMAS F	Director	2025-08-25	P	50,000	$1.15	$57,500
2025-08-19	KIRK THOMAS F	Director	2025-08-18	P	50,000	$1.10	$55,000
2025-08-18	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2025-08-15	P	50,000	$0.95	$47,295
2025-07-02	Kovelman Harry	Officer (Chief Medical Officer)	2025-06-30	F	(13,054)	$2.19	-$28,588
2025-07-02	HENRY DAVID A	Officer (Chief Financial Officer)	2025-06-30	F	(23,587)	$2.19	-$51,656
2025-06-13	Kovelman Harry	Officer (Chief Medical Officer)	2025-06-11	A	62,938	—	$0
2025-06-13	Mitchell Micah	Officer (Chief Commercial Officer)	2025-06-11	A	59,440	—	$0
2025-06-13	HENRY DAVID A	Officer (Chief Financial Officer)	2025-06-11	A	76,398	—	$0
2025-06-13	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2025-06-11	A	157,342	—	$0
2025-06-12	KIRK THOMAS F	Director	2025-06-11	A	29,720	—	$0
2025-06-12	Crowley Thomas Aloysius Jr.	Director	2025-06-11	A	29,720	—	$0
2025-06-12	Morris Milton Mayo	Director	2025-06-11	A	29,720	—	$0
2025-06-12	Getz Heather C	Director	2025-06-11	A	29,720	—	$0
2025-06-06	Kovelman Harry	Officer (Chief Medical Officer)	2025-06-06	F	(5,743)	$2.97	-$17,057
2025-06-06	HENRY DAVID A	Officer (Chief Financial Officer)	2025-06-06	F	(8,373)	$2.97	-$24,868
2025-05-15	KIRK THOMAS F	Director	2025-05-15	P	36,824	$3.25	$119,678
2025-05-15	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2025-05-15	P	30,000	$3.22	$96,612
2025-05-15	KIRK THOMAS F	Director	2025-05-14	P	1,943	$3.25	$6,315
2025-05-14	KIRK THOMAS F	Director	2025-05-12	P	50,000	$3.35	$167,500
2025-03-21	Mitchell Micah	Officer (Chief Commercial Officer)	2025-03-14	S	(48,000)	$5.16	-$247,565
2025-03-14	Mitchell Micah	Officer (Chief Commercial Officer)	2025-03-14	S	(48,000)	$5.16	-$247,565
2025-03-14	Mitchell Micah	Officer (Chief Commercial Officer)	2025-03-14	S	(48,000)	$5.16	-$247,565
2025-03-14	KIRK THOMAS F	Director	2025-03-13	P	7,400	$5.00	$37,000
2025-03-14	Mitchell Micah	Officer (Chief Commercial Officer)	2025-03-13	F	(1,283)	$5.22	-$6,697
2025-03-14	Mitchell Micah	Officer (Chief Commercial Officer)	2025-03-11	A	3,737	—	$0
2025-03-13	Kovelman Harry	Officer (Chief Medical Officer)	2025-03-13	F	(1,496)	$5.22	-$7,809
2025-03-13	HENRY DAVID A	Officer (Chief Financial Officer)	2025-03-13	F	(2,019)	$5.22	-$10,539
2025-03-13	Mitchell Micah	Officer (Chief Commercial Officer)	2025-03-13	F	(1,283)	$5.22	-$6,697
2025-03-13	Kovelman Harry	Officer (Chief Medical Officer)	2025-03-12	S	(30,000)	$5.50	-$165,018
2025-03-13	Kovelman Harry	Officer (Chief Medical Officer)	2025-03-11	A	3,553	—	$0
2025-03-13	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2025-03-11	A	6,708	—	$0
2025-03-13	HENRY DAVID A	Officer (Chief Financial Officer)	2025-03-11	A	4,106	—	$0
2025-03-13	Mitchell Micah	Officer (Chief Commercial Officer)	2024-03-11	A	3,737	—	$0
2025-02-18	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2025-02-13	M	694	$0.05	$33
2025-02-18	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2025-02-13	M	(694)	—	$-0
2025-01-24	Mitchell Micah	Officer (Chief Commercial Officer)	2024-06-09	M	1,717	—	$0
2025-01-24	Mitchell Micah	Officer (Chief Commercial Officer)	2024-06-09	M	(1,717)	—	$-0
2025-01-24	HENRY DAVID A	Officer (Chief Financial Officer)	2024-06-09	M	3,012	—	$0
2025-01-24	HENRY DAVID A	Officer (Chief Financial Officer)	2024-06-09	M	(3,012)	—	$-0
2025-01-24	Kovelman Harry	Officer (Chief Medical Officer)	2024-06-09	M	1,235	—	$0
2025-01-24	Kovelman Harry	Officer (Chief Medical Officer)	2024-06-09	M	(1,235)	—	$-0
2025-01-24	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2024-06-09	M	6,024	—	$0
2025-01-24	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2024-06-09	M	(6,024)	—	$-0
2025-01-22	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2024-06-05	A	130,000	—	$0
2024-11-05	Kovelman Harry	Officer (Chief Medical Officer)	2024-11-04	F	(121)	$3.70	-$448
2024-10-04	Kovelman Harry	Officer (Chief Medical Officer)	2024-10-03	F	(121)	$3.86	-$467
2024-09-09	Kovelman Harry	Officer (Chief Medical Officer)	2024-09-05	S	(6,700)	$3.76	-$25,183
2024-09-05	Kovelman Harry	Officer (Chief Medical Officer)	2024-09-04	F	(139)	$3.89	-$541
2024-09-05	Kovelman Harry	Officer (Chief Medical Officer)	2024-09-03	S	(2,029)	$4.01	-$8,140
2024-08-07	Kovelman Harry	Officer (Chief Medical Officer)	2024-08-05	F	(128)	$3.96	-$507
2024-07-08	Kovelman Harry	Officer (Chief Medical Officer)	2024-07-03	F	(121)	$2.85	-$345
2024-07-02	Mitchell Micah	Officer (Chief Commercial Officer)	2024-07-01	F	(15,500)	$3.02	-$46,810
2024-07-02	Kovelman Harry	Officer (Chief Medical Officer)	2024-07-01	F	(12,868)	$3.02	-$38,861
2024-07-02	HENRY DAVID A	Officer (Chief Financial Officer)	2024-07-01	F	(25,436)	$3.02	-$76,817
2024-07-02	Mitchell Micah	Officer (Chief Commercial Officer)	2024-06-10	F	(6,837)	$3.38	-$23,089
2024-07-02	Kovelman Harry	Officer (Chief Medical Officer)	2024-06-10	F	(5,347)	$3.38	-$18,068
2024-06-12	HENRY DAVID A	Officer (Chief Financial Officer)	2024-06-10	F	(10,620)	$3.38	-$35,853
2024-06-12	Kovelman Harry	Officer (Chief Medical Officer)	2024-06-10	F	5,347	$3.38	$18,068
2024-06-12	Mitchell Micah	Officer (Chief Commercial Officer)	2024-06-10	F	6,837	$3.38	$23,089
2024-06-07	HENRY DAVID A	Officer (Chief Financial Officer)	2024-06-05	A	70,000	—	$0
2024-06-07	Mitchell Micah	Officer (Chief Commercial Officer)	2024-06-05	A	50,000	—	$0
2024-06-07	Kovelman Harry	Officer (Chief Medical Officer)	2024-06-05	A	53,000	—	$0
2024-06-07	GUDONIS PAUL R	Director, Officer (Chief Executive Officer)	2024-06-05	A	130,000	—	$0
2024-06-07	KIRK THOMAS F	Director	2024-06-05	A	12,034	—	$0
2024-06-07	Morris Milton Mayo	Director	2024-06-05	A	12,034	—	$0
2024-06-07	Crowley Thomas Aloysius Jr.	Director	2024-06-05	A	12,034	—	$0
2024-06-07	Getz Heather C	Director	2024-06-05	A	12,034	—	$0
2024-06-07	Knapp Amy K.	Director	2024-06-05	A	12,034	—	$0
2024-06-05	Kovelman Harry	Officer (Chief Medical Officer)	2024-06-03	F	(121)	$3.48	-$421
2024-05-31	KIRK THOMAS F	Director	2024-05-29	P	50,000	$3.50	$175,000